170 related articles for article (PubMed ID: 38304914)
1. Ultrasound-mediated drug-free theranostics for treatment of prostate cancer.
Perera RH; Berg FM; Abenojar EC; Nittayacharn P; Kim Y; Wang X; Basilion JP; Exner A
Bioact Mater; 2024 May; 35():45-55. PubMed ID: 38304914
[TBL] [Abstract][Full Text] [Related]
2. Ultrasound-mediated drug-free theranostics for treatment of prostate cancer.
Perera RH; Berg FM; Abenojar EC; Nittayacharn P; Kim Y; Wang X; Basilion JP; Exner AA
bioRxiv; 2023 Sep; ():. PubMed ID: 37745586
[TBL] [Abstract][Full Text] [Related]
3. Optimized Anti-Prostate-Specific Membrane Antigen Single-Chain Variable Fragment-Loaded Nanobubbles as a Novel Targeted Ultrasound Contrast Agent for the Diagnosis of Prostate Cancer.
Ding Y; Cao Q; Qian S; Chen X; Xu Y; Chen J; Shen H
J Ultrasound Med; 2020 Apr; 39(4):761-773. PubMed ID: 31702068
[TBL] [Abstract][Full Text] [Related]
4. Quantification of extravasation and binding of PSMA-targeted nanobubbles by modelling the second-wave phenomenon.
Chen C; Perera R; Mischi M; Kolios M; Exner A; Turco S
Mol Imaging Biol; 2024 Apr; 26(2):253-263. PubMed ID: 38151581
[TBL] [Abstract][Full Text] [Related]
5. Real time ultrasound molecular imaging of prostate cancer with PSMA-targeted nanobubbles.
Perera RH; de Leon A; Wang X; Wang Y; Ramamurthy G; Peiris P; Abenojar E; Basilion JP; Exner AA
Nanomedicine; 2020 Aug; 28():102213. PubMed ID: 32348874
[TBL] [Abstract][Full Text] [Related]
6. Targeted Nanobubbles Carrying Indocyanine Green for Ultrasound, Photoacoustic and Fluorescence Imaging of Prostate Cancer.
Wang Y; Lan M; Shen D; Fang K; Zhu L; Liu Y; Hao L; Li P
Int J Nanomedicine; 2020; 15():4289-4309. PubMed ID: 32606678
[TBL] [Abstract][Full Text] [Related]
7. Intracellular vesicle entrapment of nanobubble ultrasound contrast agents targeted to PSMA promotes prolonged enhancement and stability
Perera RH; Abenojar E; Nittayacharn P; Wang X; Ramamurthy G; Peiris P; Bederman I; Basilion JP; Exner AA
Nanotheranostics; 2022; 6(3):270-285. PubMed ID: 35223380
[TBL] [Abstract][Full Text] [Related]
8. Efficient ultrasound-mediated drug delivery to orthotopic liver tumors - Direct comparison of doxorubicin-loaded nanobubbles and microbubbles.
Nittayacharn P; Abenojar E; Cooley MB; Berg FM; Counil C; Sojahrood AJ; Khan MS; Yang C; Berndl E; Golczak M; Kolios MC; Exner AA
J Control Release; 2024 Mar; 367():135-147. PubMed ID: 38237687
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic modeling of PSMA-targeted nanobubbles for quantification of extravasation and binding in mice models of prostate cancer.
Chen C; Perera R; Kolios MC; Wijkstra H; Mischi M; Exner AA; Turco S
Med Phys; 2022 Oct; 49(10):6547-6559. PubMed ID: 36049109
[TBL] [Abstract][Full Text] [Related]
10. Efficient ultrasound-mediated drug delivery to orthotopic liver tumors - Direct comparison of doxorubicin-loaded nanobubbles and microbubbles.
Nittayacharn P; Abenojar E; Cooley M; Berg F; Counil C; Sojahrood AJ; Khan MS; Yang C; Berndl E; Golczak M; Kolios MC; Exner AA
bioRxiv; 2023 Sep; ():. PubMed ID: 37732235
[TBL] [Abstract][Full Text] [Related]
11. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
[TBL] [Abstract][Full Text] [Related]
13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424
[TBL] [Abstract][Full Text] [Related]
15. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.
Xiang B; Dong DW; Shi NQ; Gao W; Yang ZZ; Cui Y; Cao DY; Qi XR
Biomaterials; 2013 Sep; 34(28):6976-91. PubMed ID: 23777916
[TBL] [Abstract][Full Text] [Related]
16. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.
Lückerath K; Wei L; Fendler WP; Evans-Axelsson S; Stuparu AD; Slavik R; Mona CE; Calais J; Rettig M; Reiter RE; Herrmann K; Radu CG; Czernin J; Eiber M
EJNMMI Res; 2018 Oct; 8(1):96. PubMed ID: 30374743
[TBL] [Abstract][Full Text] [Related]
18. Magnetic polymeric nanobubbles with optimized core size for MRI/ultrasound bimodal molecular imaging of prostate cancer.
Zhu Y; Sun Y; Liu W; Guan W; Liu H; Duan Y; Chen Y
Nanomedicine (Lond); 2020 Dec; 15(30):2901-2916. PubMed ID: 33300812
[No Abstract] [Full Text] [Related]
19. Development of a novel castration-resistant orthotopic prostate cancer model in New Zealand White rabbit.
Wang Y; Abenojar EC; Wang J; de Leon AC; Tavri S; Wang X; Gopalakrishnan R; Walker E; MacLennan GT; Giles A; Czarnota GJ; Basilion JP; Exner AA
Prostate; 2022 May; 82(6):695-705. PubMed ID: 35167141
[TBL] [Abstract][Full Text] [Related]
20. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.
Huang CT; Guo X; Bařinka C; Lupold SE; Pomper MG; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
Mol Pharm; 2020 Sep; 17(9):3392-3402. PubMed ID: 32803984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
